Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 18/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828061 | 0.95 | BDKRB1 (0.49) | BDKRB1EPHX2CYP46A1 | |
| SCHEMBL5131391 | 0.86 | AVPR1A (0.47) | BDKRB1 | |
| SCHEMBL5128208 | 0.85 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL3808576 | 0.83 | BDKRB1 (0.50) | BDKRB1EPHX2 | |
| SCHEMBL5125344 | 0.82 | BDKRB1 (0.46) | BDKRB1 | |
| SCHEMBL5132318 | 0.81 | ALDH1A1 (0.52) | BDKRB1CYP46A1 | |
| SCHEMBL3812962 | 0.81 | ALDH1A1 (0.50) | BDKRB1 | |
| SCHEMBL5125258 | 0.80 | BDKRB1 (0.44) | BDKRB1CYP46A1 | |
| SCHEMBL3814089 | 0.80 | MEN1 (0.46) | BDKRB1 | |
| SCHEMBL5131099 | 0.80 | PKLR (0.54) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | claimed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2086935-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008046573-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | BDKRB1 1/4885EPHX2 1287/4885CYP46A1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.